INTRAVENOUS FERRIC CARBOXYMALTOSE IN THE TREATMENT OF HEART FAILURE: EFFECTS ON PATIENTS WITH PRESERVED AND REDUCED EJECTION FRACTION
Abstract
Iron deficiency significantly impacts heart failure (HF), exacerbating mitochondrial dysfunction and oxidative stress. Studies suggest that iron replenishment, especially via ferric carboxymaltose (FCM), improves functional capacity and prognosis in patients with HF and iron deficiency. This study aims to analyze the effects of FCM in different ejection fraction profiles, contributing to the improvement of therapeutic management of HF. Objective: To review the literature on the efficacy of intravenous iron replenishment with FCM in patients with HF, both with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), evaluating its impacts on functional capacity, symptoms, and hospitalizations. Methods: The review was conducted with articles from the last 16 years, consulting PubMed, Scielo, Embase, and MedLine. Five original studies and reviews were selected, focusing on the efficacy of intravenous ferric carboxymaltose in heart failure, with strict inclusion and exclusion criteria. Results and Discussion: Treatment with ferric carboxymaltose (FCM) showed significant benefits in patients with heart failure and iron deficiency, improving functional capacity, symptoms, and quality of life. FCM supplementation increased exercise capacity and ventricular function, with no severe adverse effects. However, limitations such as the small number of patients and lack of changes in some biomarkers suggest the need for further studies. Conclusion: FCM therapy improved exercise capacity and cardiovascular function in heart failure, but limitations suggest the need for more studies to assess long-term effects and in different profiles.
Author Biographies
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
Estudante de Medicina, Centro Universitário de Goiatuba-Unicerrado.
References
ALNUWAYSIR, R. I. S.; HOES, M. F.; VAN VELDHUISEN, D. J.; VAN DER MEER, P.; GROTE BEVERBORG, N. Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. Journal of clinical medicine, v. 11, n. 1, p. 125, 2021. https://doi.org/10.3390/jcm11010125 DOI: https://doi.org/10.3390/jcm11010125
ANKER, S. D.; COMIN COLET, J.; FILIPPATOS, G.; WILLENHEIMER, R.; DICKSTEIN, K.; DREXLER, H.; LÜSCHER, T. F.; BART, B.; BANASIAK, W.; NIEGOWSKA, J.; KIRWAN, B. A.; MORI, C.; VON EISENHART ROTHE, B.; POCOCK, S. J.; POOLE-WILSON, P. A.; PONIKOWSKI, P. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med., v. 361, n. 25, p. 2436-48, 17 dec. 2009 DOI: https://doi.org/10.1056/NEJMoa0908355 DOI: https://doi.org/10.1056/NEJMoa0908355
BAKOGIANNIS, C.; BRIASOULIS, A.; MOUSELIMIS, D.; TSAROUCHAS, A.; PAPAGEORGIOU, N.; PAPADOPOULOS, C.; FRAGAKIS, N.; VASSILIKOS, V. Iron deficiency as therapeutic target in heart failure: a translational approach. Heart Fail Rev., v. 25, p. 173–182, 2020. DOI: https://doi.org/10.1007/s10741-019-09815-z
MOLLACE, A.; MACRÌ, R.; MOLLACE, R.; TAVERNESE, A.; GLIOZZI, M.; MUSOLINO, V.; CARRESI, C.; MAIUOLO, J.; NICITA, M.; CAMINITI, R.; PAONE, S.; BARILLÀ, F.; VOLTERRANI, M.; MOLLACE, V. Effect of Ferric Carboxymaltose Supplementation in Patients with Heart Failure with Preserved Ejection Fraction: Role of Attenuated Oxidative Stress and Improved Endothelial Function. Nutrients, v. 14, n. 23, p. 5057, 28 nov. 2022 DOI: https://doi.org/10.3390/nu14235057 DOI: https://doi.org/10.3390/nu14235057
PONIKOWSKI, Piotr; VAN VELDHUISEN, Dirk J.; COMIN-COLET, Josep; ERTL, Georg; KOMAJDA, Michel; MAREEV, Viacheslav; MCDONAGH, Theresa; PARKHOMENKO, Alexander; TAVAZZI, Luigi; LEVESQUE, Victoria; MORI, Claudio; ROUBERT, Bernard; FILIPPATOS, Gerasimos; RUSCHITZKA, Frank; ANKER, Stefan D. For the CONFIRM-HF Investigators, Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal, v. 36, Issue 11, p. 657–668, 14 March 2015. https://doi.org/10.1093/eurheartj/ehu385 DOI: https://doi.org/10.1093/eurheartj/ehu385
ROGNONI, C.; GERZELI, S. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact. Journal of comparative effectiveness research, v. 8, n. 13, p. 1099–1110, 2019. https://doi.org/10.2217/cer-2019-0074 DOI: https://doi.org/10.2217/cer-2019-0074
VON HAEHLING, S.; DOEHNER, W.; EVERTZ, R.; GARFIAS-VEITL, T.; DERAD, C.; DIEK, M.; KARAKAS, M.; BIRKEMEYER, R.; FILLIPPATOS, G.; LAINSCAK, M.; BUTLER, J.; PONIKOWSKI, P.; BÖHM, M.; FRIEDE, T.; ANKER, S. D. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J., v. 45, n. 37, p. 3789-3800, 5 oct. 2024 DOI: https://doi.org/10.1093/eurheartj/ehae479
VON HAEHLING, Stephan; DOEHNER, Wolfram; EVERTZ, Ruben; GARFIAS-VEITL, Tania; DERAD, Carlotta; DIEK, Monika; KARAKAS, Mahir; BIRKEMEYER, Ralf; FILLIPPATOS, Gerasimos; LAINSCAK, Mitja; BUTLER, Javed; PONIKOWSKI, Piotr; BÖHM, Michael; FRIEDE, Tim F.; ANKER, Stefan D. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. European Heart Journal, v. 45, Issue 37, p. 3789–3800,1 October 2024. https://doi.org/10.1093/eurheartj/ehae479 DOI: https://doi.org/10.1093/eurheartj/ehae479
License
Copyright (c) 2025 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.